Cargando…

Postoperative radioiodine therapy impact on survival in poorly differentiated thyroid carcinoma: a population-based study

The true impact of postoperative radioiodine therapy on survival has been controversial for patients with poorly differentiated thyroid carcinoma (PDTC). We aimed to determine the impact of postoperative radioiodine on survival in PDTC through a population-based study. METHODS: Data on patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Lei, Zou, Qiong, Jiao, Ju, Zhang, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754091/ https://www.ncbi.nlm.nih.gov/pubmed/34711774 http://dx.doi.org/10.1097/MNM.0000000000001499

Ejemplares similares

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Myopathy following postoperative ablative radioiodine for follicular carcinoma of the thyroid
por: Price, Hermione C, et al.
Publicado: (2009)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy
por: Wang, Congcong, et al.
Publicado: (2023)

Alterations in Oral Microbiota of Differentiated Thyroid Carcinoma Patients With Xerostomia After Radioiodine Therapy
por: Lin, Baiqiang, et al.
Publicado: (2022)

False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer
por: Barbaro, Daniele, et al.
Publicado: (2023)

Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
por: Feola, Tiziana, et al.
Publicado: (2021)

Development and validation of nomograms for predicting survival in differentiated thyroid cancer patients with or without radioiodine therapy
por: Ran, Bingyu, et al.
Publicado: (2023)

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma
por: Zagar, Ivana, et al.
Publicado: (2012)

Solitary Metacarpophalangeal Metastasis from Poorly Differentiated Thyroid Carcinoma: Excellent Tumor Marker and Scan Response to Two Fractions of Radioiodine Therapy
por: Suman, Sonam, et al.
Publicado: (2018)

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer
por: Pacilio, Massimiliano, et al.
Publicado: (2022)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
por: Sun, Yu-qing, et al.
Publicado: (2022)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

MON-LB76 Impact of Age on Survival and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Cancer Patients
por: Buffet, Camille
Publicado: (2020)

Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology
por: Chung, June-Key, et al.
Publicado: (2014)

Dietary Iodine Intake, Therapy with Radioiodine, and Anaplastic Thyroid Carcinoma
por: Besic, Nikola, et al.
Publicado: (2020)

Oxidative stress and radioiodine treatment of differentiated thyroid cancer
por: Buczyńska, Angelika, et al.
Publicado: (2021)

Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer
por: Petranović Ovčariček, Petra, et al.
Publicado: (2023)

Dacryoendoscopic recanalization of lacrimal passage obstruction/stenosis after radioiodine therapy for differentiated thyroid carcinoma
por: Inomata, Daniela, et al.
Publicado: (2022)

The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma
por: Dizdarevic, S, et al.
Publicado: (2019)

Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
por: Hay, Ian D, et al.
Publicado: (2022)

(99m)Tc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities
por: Giovanella, Luca, et al.
Publicado: (2019)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Tracheal Obstruction by an Invading Well-Differentiated Thyroid Carcinoma
por: Pontikides, Nickolaos, et al.
Publicado: (2013)

Gastrointestinal Side Effects of the Radioiodine Therapy for the Patients with Differentiated Thyroid Carcinoma Two Days after Prescription
por: Pashnehsaz, Mehran, et al.
Publicado: (2016)

Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review
por: Sheu, Nai-Wei, et al.
Publicado: (2019)

Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
por: Wang, Congcong, et al.
Publicado: (2021)

Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy
por: Burgard, Caroline, et al.
Publicado: (2023)

Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
por: Busaidy, Naifa Lamki, et al.
Publicado: (2012)

Faecalibacterium prausnitzii in Differentiated Thyroid Cancer Patients Treated with Radioiodine
por: Fernandes, Ana, et al.
Publicado: (2023)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

High RPMB predicts poor disease-free survival of male N1 papillary thyroid cancer after adjuvant radioiodine therapy
por: An, Ning, et al.
Publicado: (2022)

Clinical significance of extra-thyroid (99m)Tc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma
por: Long, Bin, et al.
Publicado: (2021)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

Weathering the Storm: Thyroid Storm Precipitated by Radioiodine Contrast in Metastatic Thyroid Carcinoma
por: Basida, Brinda, et al.
Publicado: (2021)

Ultrasound-guided implantation of radioactive (125)I seed in radioiodine refractory differentiated thyroid carcinoma
por: Chen, Wei, et al.
Publicado: (2021)

Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma
por: Qiu, Xian, et al.
Publicado: (2022)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
por: Satapathy, Swayamjeet, et al.
Publicado: (2022)

Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective
por: Nervo, Alice, et al.
Publicado: (2022)

Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma
por: Kaewchur, Tawika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3np9sg7uhhasdtd0jeqatbh1s6